CD36 and atherosclerosis: TMAO contributes to the degenerative phase of atherosclerosis development by promoting macrophage movement and further augments atherosclerotic lesions by increasing the expression of macrophage scavenger receptors CD-36 and the SR-A1, inducing foam cell formation and impairment of in vivo RCT [46].